Compare Monolithic Power Systems Inc (MPWR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Moderna, Inc. — how do they compare? Monolithic Power Systems Inc trades at $1,399.99 (market cap $70.08B), while Moderna, Inc. trades at $195.7 (market cap $78.44B). The key difference: Monolithic Power Systems Inc and Moderna, Inc. are close in size by market cap, and Monolithic Power Systems Inc pays a 0.56% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Moderna, Inc. for 59 Days on average.
| MPWR | MRNA | |
|---|---|---|
Market Cap | $70.08B | $78.44B |
Volume | 480,594 | 14,597,511 |
Sector | Technology | Health |
52-Week High | $1.69K | $203.46 |
52-Week Low | $856.96 | $22.36 |
Typical Hold Time | 25 Days | 59 Days |
Enterprise Value | $68.68B | $74.59B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,425.98, down 3.24% on the day, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 24.5% net income margin and 21.98% ROE, though valuation metrics remain elevated at 87 P/E. Recent earnings beats and a manufacturing partnership with GlobalFoundries signal continued growth potential in AI and data center markets.
MPWR presents a compelling growth story driven by AI infrastructure demand, but faces valuation concerns and insider selling pressure. The stock's 88% buy rating consensus and $1,830 price target suggest 28% upside potential, though investors should weigh premium valuation against strong execution and market positioning.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
